AQST - Aquestive Therapeutics Inc. (AQST) Q1 2024 Earnings Call Transcript
2024-05-08 12:32:09 ET
Aquestive Therapeutics, Inc. (AQST)
Q1 2024 Earnings Conference Call
May 08, 2024 8:00 AM ET
Company Participants
Bennett Watson – ICR Westwicke Investor Relations
Dan Barber – Chief Executive Officer and President
Ernie Toth – Chief Financial Officer
Stephen Wargacki – Chief Science Officer
Conference Call Participants
David Amsellem – Piper Sandler
Francois Brisebois – Oppenheimer
Ram Selvaraju – H.C. Wainwright
Gary Nachman – Raymond James
Thomas Flaten – Lake Street Capital Markets
Presentation
Operator
Good morning, and welcome to Aquestive Therapeutics First Quarter 2024 Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, we will conduct a question-and-answer session. [Operator Instructions] As a reminder, this call will be recorded.
I would now like to introduce your host for today's conference call, Bennett Watson of ICR Westwicke Investor Relations. You may begin.
Bennett Watson
Thank you, operator. Good morning, and welcome to today's call. On today's call, I'm joined by Dan Barber, Chief Executive Officer; and Ernie Toth, Chief Financial Officer, who are going to provide an overview of recent business developments and performance for the first quarter 2024, followed by a Q&A session. During the Q&A session, the team will be joined by Dr. Stephen Wargacki, Chief Science Officer.
As a reminder, the company's remarks today correspond with the earnings release that was issued after market close yesterday. In addition, a recording of today's call will be made available on Aquestive's website within the Investors section shortly following the conclusion of this call. To remind you, the Aquestive team will be discussing some non-GAAP financial measures this morning as part of its review of first quarter 2024 results. A description of these measures along with a reconciliation to GAAP can be found in the earnings release issued yesterday, which is posted on the Investors section of Aquestive's website.
During the call, the company will be making forward-looking statements. We remind you of the company's safe harbor language as outlined in yesterday's earnings release as well as the risks and uncertainties affecting the company as described in the Risk Factors section and in other sections included in the company's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on May 07, 2024. As with any pharmaceutical company, with product candidates under development and products being commercialized, there are significant risks and uncertainties with respect to the company's business and the development, regulatory approval and commercialization of its products and other matters related to operations. Given these uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. Actual results may differ materially from these statements....
Aquestive Therapeutics, Inc. (AQST) Q1 2024 Earnings Call Transcript